At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes
In Brief
A Phase 2 clinical trial evaluating Interleukin-2 [IL-2] and Placebo Dextrose 5% solution for Acute Coronary Syndromes. Completed, enrolled 60 participants across 1 site.
Detailed Summary
Acute coronary syndromes (ACS) result from coronary plaque(s) disruption, which initiates a thrombotic process leading to partial or complete obstruction of the vessel lumen with subsequent myocardial ischaemia and necrosis. The mainstay of treatment is currently focused on the re-establishment and maintenance of coronary artery patency using anti-platelets and anticoagulants with or without mechanical dilatation and stenting of the culprit artery. Despite important advances in management, ACS still carries a risk of substantial morbidity and mortality. The improved efficacy of novel anti-platelet and anticoagulant agents have been limited by increased risk of haemorrhagic events. Future breakthroughs in management are most likely to arise from targeting other relevant pathophysiological pathways. Particularly, the immune response which is an important process that has been neglected in the management of patients with ACS. In this trial the investigators investigate the efficacy of low dose IL-2 compared with placebo in patients with ACS.
Study Details
Timeline
Interventions
Active Comparator: IL-2 plays a key role in Treg cell development, expansion, survival and suppressive function
Placebo Comparator: Dextrose 5% solution